To: [redacted][[redacted]@minvws.nl]; [redacted][[redacted]@rivm.nl]
From: [redacted]
Sent: Tue 11/24/2020 7:09:25 PM
Subject: RE: AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
Received: Tue 11/24/2020 7:09:25 PM

[redacted]

Dank, nee geen nieuwe inzichten.

Het is het persbericht dat maandag beschikbaar kwam.

Fijne avond,

[redacted]

From: [redacted]. <[redacted]@minvws.nl>
Sent: dinsdag 24 november 2020 19:08
To: [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>
Subject: FW: AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

[redacted]

Biedt dit nieuwe inzichten?

Groet,
[redacted]

Verzonden met BlackBerry Work
(www.blackberry.com)

Van: [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>
Datum: dinsdag 24 nov. 2020 6:49 PM
Aan: [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@bmg.bund.de <[redacted]@bmg.bund.de>, [redacted]@aemps.es <[redacted]@aemps.es>, [redacted]@bmg.bund.de <[redacted]@bmg.bund.de>, [redacted]@sanita.it <[redacted]@sanita.it>, [redacted]@igf.finances.gouv.fr <[redacted]@igf.finances.gouv.fr>, [redacted]@pm.gouv.fr <[redacted]@pm.gouv.fr>, [redacted]@ec.europa.eu <[redacted]@ec.europa.eu>, [redacted]@bmg.bund.de <[redacted]@bmg.bund.de>, [redacted]@pzh.gov.pl <[redacted]@pzh.gov.pl>, [redacted]@gov.se <[redacted]@gov.se>, [redacted]. <[redacted]@minvws.nl>
Onderwerp: FW: AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

We should share this with the Steering.

Best, [redacted]

From [redacted] <[redacted]@astrazeneca.com> **On Behalf Of** [redacted]
Sent: Monday, November 23, 2020 8:06 AM
To: [redacted] (SANTE) <[redacted]@ec.europa.eu>

Cc: 5.1.2e 5.1.2e @astrazeneca.com 5.1.2e ; 5.1.2e @astrazeneca.com>; 5.1.2e , 5.1.2e
< 5.1.2e @astrazeneca.com>; 5.1.2e < 5.1.2e @astrazeneca.com>
Subject: AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Dear 5.1.2e

I am pleased to inform you that AstraZeneca has just announced positive high-level results from an interim analysis of AZD1222 trials in the UK and Brazil. The data show that the vaccine was highly effective in preventing COVID-19 infection, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.

Two different dosing regimens demonstrated efficacy with one showing a better profile. One dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart.

No serious safety events have been confirmed related to the vaccine and AZD1222 was well tolerated across both dosing regimens, with even fewer adverse reactions seen in the regimen showing 90% efficacy. The full analysis of the interim results is being submitted for publication in a peer-reviewed journal. AstraZeneca will now immediately prepare regulatory submission of the data to authorities around the world including the European Medicines Agency (EMA).

This vaccine's efficacy and safety confirm that it will have an immediate impact on this public health emergency, reducing hospitalisations and saving lives. Meanwhile, the promise of the 90% efficacy of the low dose regimen means that more people can potentially be vaccinated more quickly with existing dose capacity in Europe and around the world. The vaccine can be stored, transported and handled at 2-8 °C (about 34-42 °F) for at least six months, enabling easy use within existing healthcare settings.

Please see here the official company announcement with further information.

We would like to thank you for your continued partnership and would welcome the opportunity to meet with you to discuss today's announcement in greater detail.

Best regards,

5.1.2e
EVP Europe and Canada
AstraZeneca | Neuhofstrasse 34, 6340 Baar
E: 5.1.2e @astrazeneca.com